reduced hospitalization Archives - Amazing Health Advances https://amazinghealthadvances.net/tag/reduced-hospitalization/ Your hub for fresh-picked health and wellness info Tue, 04 Jan 2022 00:56:48 +0000 en-US hourly 1 https://wordpress.org/?v=6.8.1 https://amazinghealthadvances.net/wp-content/uploads/2019/08/AHA_Gradient_Bowl-150x150.jpg reduced hospitalization Archives - Amazing Health Advances https://amazinghealthadvances.net/tag/reduced-hospitalization/ 32 32 New Study Shows Weight-Loss Surgery Significantly Cut Risk of Severe Complications From COVID-19 in Patients with Obesity https://amazinghealthadvances.net/new-study-shows-weight-loss-surgery-significantly-cut-risk-of-severe-complications-from-covid-19-in-patients-with-obesity-7771/#utm_source=rss&utm_medium=rss&utm_campaign=new-study-shows-weight-loss-surgery-significantly-cut-risk-of-severe-complications-from-covid-19-in-patients-with-obesity-7771 https://amazinghealthadvances.net/new-study-shows-weight-loss-surgery-significantly-cut-risk-of-severe-complications-from-covid-19-in-patients-with-obesity-7771/#respond Tue, 04 Jan 2022 08:00:35 +0000 https://amazinghealthadvances.net/?p=13754 American Society for Metabolic and Bariatric Surgery (ASMBS) via Newswise – NEWBERRY, FL – Dec. 29, 2021 – Adults with obesity who had weight-loss surgery and achieved substantial weight loss prior to contracting COVID-19 reduced their risk for developing severe outcomes from the infection by 60% compared to those who did not have surgery, according to a new Cleveland Clinic study published online today in the journal JAMA Surgery. According to the U.S. Centers for Disease Control and Prevention (CDC), having obesity increases the risk of severe illness from COVID. “This is an important study that shows that patients with obesity who had bariatric surgery and subsequently developed COVID-19 had greatly reduced their risk for hospitalization, supplemental oxygen, and severe infection compared to similar patients that did not have bariatric surgery,” said Shanu N. Kothari, MD, president of the American Society for Metabolic and Bariatric Surgery (ASMBS), who was not involved in the study. “This timely study should serve as further motivation for patients and their doctors to treat the disease of obesity before potentially having to treat its dangerous consequences.”  Obesity is linked to more than 40 diseases including type 2 diabetes, hypertension, heart disease, stroke, sleep apnea, osteoarthritis and at least 13 different types of cancer. The CDC reports that from 1999 –2000 through 2017 –2018, the prevalence of obesity in the U.S. increased from 30% to 42% and severe obesity increased from 4.7% to 9.2%. Metabolic/bariatric surgery has been shown to be the most effective and durable treatment for severe obesity, resulting in significant weight loss and resolution or improvements in diabetes, heart disease, sleep apnea and many other diseases. The safety profile of laparoscopic bariatric surgery is comparable to some of the safest and most commonly performed surgeries in the U.S. including gallbladder surgery, appendectomy and knee replacement. An estimated 256,000 bariatric surgeries were performed in 2019, according to the ASMBS, which represents less than 1 percent of the currently eligible surgical population by BMI. Nearly 60% were sleeve gastrectomies, an increasingly popular procedure that involves removing most of the stomach and shaping the remainder into a tube or sleeve, restricting the amount of food it can hold. About 18% of procedures were gastric bypass. To read the original article click here.

The post New Study Shows Weight-Loss Surgery Significantly Cut Risk of Severe Complications From COVID-19 in Patients with Obesity appeared first on Amazing Health Advances.

]]> https://amazinghealthadvances.net/new-study-shows-weight-loss-surgery-significantly-cut-risk-of-severe-complications-from-covid-19-in-patients-with-obesity-7771/feed/ 0 Drug Saves 47 of 50 Severe Covid Patients in Trial https://amazinghealthadvances.net/drug-saves-47-of-50-severe-covid-patients-in-trial-7704/#utm_source=rss&utm_medium=rss&utm_campaign=drug-saves-47-of-50-severe-covid-patients-in-trial-7704 https://amazinghealthadvances.net/drug-saves-47-of-50-severe-covid-patients-in-trial-7704/#respond Mon, 29 Nov 2021 08:23:27 +0000 https://amazinghealthadvances.net/?p=13447 Abigail Klein Leichman via Israel21c – Israel’s Bonus BioGroup reports a survival rate of 94 percent (47 of 50) of the severe Covid-19 patients treated with its drug product MesenCure in a Phase II, multicenter clinical trial. Study results, soon to be published, show MesenCure treatment reduced study participants’ hospitalization period by about half compared to a control group. All these patients had life-threatening pneumonia and respiratory distress caused by Covid-19. The data shows that MesenCure treatment reduced mortality by about 70% compared with the control group. Only two of the first 30 severe Covid-19 patients treated with MesenCure died due to Covid-19 or its complications, while 14 of 60 similar patients in the control group died. MesenCure treatment shortened the hospitalization period of severe Covid-19 patients by eight days on average, a reduction of 45% relative to the control group. The experimental group included women and men aged 41.4 to 77.4. About 77% of the severe Covid-19 patients treated in three hospitals with MesenCure had one or more risk factors for poor prognosis: hypertension, hyperlipidemia, obesity and Type 2 diabetes. Most were treated during the fourth Covid-19 wave in Israel, dominated by the Delta strain. The control group received the current standard of care — anti-inflammatory drugs in combination with steroids. This regimen, according to Bonus BioGroup, reduces mortality in hospitalized Covid-19 patients only slightly, from 25.8% to 21.8%, indicating that MesenCure is four times more effective. “We are proud of our success in leading the world to be a safer place by developing a medication for severe Covid-19 patients, thereby dramatically reducing the threat to their lives,” said Dr. Shai Meretzki, CEO of Bonus BioGroup. “In less than two years from the epidemic outbreak, we are the first in the world to report an effective and significant treatment for severely ill patients.” According to a statement from Bonus BioGroup, an independent expert committee confirmed the findings of the Phase II clinical trial of MesenCure and recommended continuing toward Phase III. Meretzki told the Jerusalem Post that the company will apply for emergency use approval from European and US regulatory agencies. To read the original article click here.

The post Drug Saves 47 of 50 Severe Covid Patients in Trial appeared first on Amazing Health Advances.

]]> https://amazinghealthadvances.net/drug-saves-47-of-50-severe-covid-patients-in-trial-7704/feed/ 0